Post a Comment Print Share on Facebook


Lung cancer, a new therapy target
FOR patients with a lung cancer non-small cell lung cancer (NSCLC) locally advanced or metastatic and who have a particular mutation of the receptor of the epidermal growth factor (EGFRm), there is now a therapeutic option in the most right from the first line of treatment. The Italian drug Agency (Aifa) has approved the reimbursement of osimertinib, an inhibitor of tyrosine kinase (TKI) of the third generation. This drug is able to act both at the level of EGFR mutations, both at the level of mutation of resistance T790M, proving to be also effective on metastases that affect the central nervous system. It is already available in Italy for the treatment in second-line patients with NSCLC EGFRm, and today it had received approval for the first-line treatment in more than 70 countries, including the United States, Japan and the Eu.
A new target therapy to the tumor changed The redeemability of osimertinb for the first-line treatment of lung cancer-small cell with mutation of EGFR is the result of the findings of the study FLAURA in which, for the first time, a therapy has been shown a major advantage in terms of overall survival and progression-free survival”, explains Filippo de Marinis, Director of the Division of Thoracic Oncology at the European Institute of Oncology (IEO) in Milan, italy that speaks of a new standard of care. “An important milestone for patients with lung cancer not to small cells with mutation of EGFR, which may, therefore, access to this treatment soon after diagnosis with benefits in terms of survival but also of safety and tolerability, important elements for the quality of life of patients,” adds Silvia Novello, Professor of Medical Oncology at the Oncology Department of the University of Turin and President of WALCE (Women Against Lung Cancer in Europe – Women Against Lung Cancer in Europe).
In the studio Osimertinib is currently being studied as adjuvant therapy (i.e. for the prevention of recurrences after surgery, study ADAURA), for patients with locally advanced, unresectable disease (study LAURA), in combination with chemotherapy (study FLAURA2) and with other potential new drugs (studies in SAVANNAH and ORCHARD).

"The Republic will fight always in defense of the freedom of information, to its readers and to all those who have at heart the principles of democracy and civil coexistence"

Carlo Verdelli SUBSCRIBERS TO REPUBLIC © Reproduction reserved Today about Trump, the war declared via Twitter, and the issue of social media with the politicians of the Usa-Iran, a step away from the war Italian soldiers in Libya are ready to evacuation Trump threat, then reconsiders: so messed up its general Crisis-Usa-Iran, the two Wests
the Republic
Your Name
Post a Comment
Characters Left:
Your comment has been forwarded to the administrator for approval.×
Warning! Will constitute a criminal offense, illegal, threatening, offensive, insulting and swearing, derogatory, defamatory, vulgar, pornographic, indecent, personality rights, damaging or similar nature in the nature of all kinds of financial content, legal, criminal and administrative responsibility for the content of the sender member / members are belong.